jueves, 15 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 24, 2026

Crypto Casinos 2026: Thunderpick Expands Worldwide with Provably Fair Games, Instant Payouts & Betting Options

View original at globenewswire.com
Crypto Casinos 2026: Thunderpick Expands Worldwide with Provably Fair Games, Instant Payouts & Betting Options New York City, NY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Waiting too long for your crypto withdrawals to clear?…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Slower banking systems and cross-border payment barriers have encouraged more players to consider crypto casinos with blockchain validation rather than bank processing

    80% confidence

  • Blockchain confirmations generally reduce processing delays compared to legacy banking methods, with users reporting quicker withdrawals once network confirmations are completed

    80% confidence

  • Industry analysts suggest that blockchain adoption in entertainment is no longer experimental and online crypto casinos have become a recognized segment within digital gaming

    80% confidence

  • Thunderpick addresses withdrawal delays and bonus term confusion with streamlined crypto payouts, clearly structured promotions, and strong focus on esports betting

    80% confidence

  • Crypto gambling sites are reporting steady engagement growth across multiple markets in 2026

    80% confidence

Citado en estos reportajes de Via News

Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,377 documentos fuente archivados
Consulta estos datos → isubstrate.com